Insights

Our CEO Allan Bradley shares an overview of T-Therapeutics, our technology and how the team is seeking to reshape the clinical landscape for cancer patients.

Phoebe Lee, a scientist in our Pipeline Expression team, gives a flavour of T-Therapeutics as a workplace, as well as the broader Cambridge life sciences ecosystem.

Camillo Moschner, PhD, a scientist in our Synthetic Biology & Automation department, talks about the importance of bringing biology and engineering closer together.

Amy Li, Director for Drug Discovery at T-Therapeutics, outlines how discoveries from the antibody field have informed the OpTiMus® platform and engineering of humanised TCRs.

Michael Casey, Principal Data Scientist, outlines how T-Therapeutics is building a soluble TCR ‘factory’ to reliably develop new medications for a range of indications.

What’s it like moving from academia to a lab role at a growing biotech? Ying Ying (Joyce) Tan, a scientist on the Target Discovery team, gives her perspective on the culture of collaboration at T-Therapeutics.

Ruben Cabanillas, Senior Director of Translational Medicine, discusses the importance of keeping the patient at the front of mind at every stage of research and development.

T-Therapeutics’ CEO Allan Bradley shares his thoughts on why a diverse, expert team with a shared vision is so vital to the future success of the business.

Dr David Hung has joined T-Therapeutics as Chairman of its Board of Directors. In this video, which accompanied the announcement, Dr Hung explains his decision: “I have always wanted to be on the cutting-edge of science and transform the practice of medicine. I…